Market research
2L9.F Blueprint Medicines Corporation
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 119
- Dividend yield
- Not available
- Beta
- 0.9
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- US09627Y1091
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 119
- Dividend yield
- Not available
- Beta
- 0.9
About
About Blueprint Medicines Corporation
Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally. The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company develops BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. Blueprint Medicines Corporation was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. The company was incorporated in 2008 and is based in Cambridge, Massachusetts. As of July 18, 2025, Blueprint Medicines Corporation operates as a subsidiary of Sanofi.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 2L9.F discussion.
5 years, 5 months ago
Blueprint Medicines Corporation is currently in a long term downtrend where the price is trading 12.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Blueprint Medicines Corporation's total revenue sank by 33.8% to $34M since the same quarter in the previous year.
Its net income has dropped by 29.2% to $-86M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.8% to $-25M since the same quarter in the previous year.
Based on the above factors, Blueprint Medicines Corporation gets an overall score of 2/5.